Skip to main content

Fragile X: Autism in the Setting of a Known Genetic Syndrome

  • Chapter
  • First Online:
Pediatric Neuropsychiatry

Abstract

Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by deficits in social communication and social interaction and restricted, repetitive patterns of behavior, interests, or activities. ASD is considered to be a multifactorial disorder, risk of which can be elevated by various hereditary causes ranging from copy number variants to monogenic disorders. Fragile X syndrome (FXS) is a neurodevelopmental disorder that is thought to be the most common inherited cause of intellectual disability and the most common monogenic cause of ASD. This chapter highlights the phenotypic, neuroanatomical, and pathophysiological similarities and differences between idiopathic ASD and ASD as the result of a known genetic syndrome and ways in which clinicians can diagnose and manage these disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM 5. 5th ed. Arlington: American Psychiatric Association; 2013.

    Book  Google Scholar 

  2. Lee M, Martin GE, Berry-Kravis E, Losh M. A developmental, longitudinal investigation of autism phenotypic profiles in fragile X syndrome. J Neurodev Disord. 2016; https://doi.org/10.1186/s11689-016-9179-0.

  3. Zafeiriou DI, Ververi A, Dafoulis V, Kalyva E, Vargiami E. Autism spectrum disorders: the quest for genetic syndromes. Am J Med Genet B Neuropsychiatr Genet. 2013;162B(4):327–66.

    Article  Google Scholar 

  4. American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children and adolescents with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2014;53(2):237–57.

    Article  Google Scholar 

  5. Erickson CA, Davenport MH, Schaefer TL, Wink LK, Pedapati EV, Sweeney JA, et al. Fragile X targeted pharmacotherapy: lessons learned and future directions. J Neurodev Disord. 2017; https://doi.org/10.1186/s11689-017-9186-9.

  6. Bagni C, Oostra BA. Fragile X syndrome: from protein function to therapy. Am J Med Genet. 2013;161A(11):2809–21.

    Article  Google Scholar 

  7. Belmonte MK, Bourgeron T. Fragile X syndrome and autism at the intersection of genetic and neural networks. Nat Neurosci. 2006;9(10):1221–5.

    Article  CAS  Google Scholar 

  8. Schaefer TL, Davenport MH, Grainger LM, Robinson CK, Earnheart AT, Stegman MS, et al. Acamprosate in a mouse model of fragile X syndrome: modulation of spontaneous cortical activity, ERK1/2 activation, locomotor activity and anxiety. J Neurodev Disord. 2017; https://doi.org/10.1186/s11689-017-9184-y.

  9. Hazlett HC, Poe MD, Lightbody AA, Styner M, MacFall JR, Reiss AL, et al. Trajectories of early brain volume development in fragile X syndrome and autism. J Am Acad Child Adolesc Psychiatry. 2012;51(9):921–33.

    Article  Google Scholar 

  10. Berry-Kravis E, Hagerman R, Visootsak J, Budimirovic D, Kaufman WE, Cherubini M, et al. Arbaclofen in fragile X syndrome: results of phase 3 trials. J Neurodev Disord. 2017; https://doi.org/10.1186/s11689-016-9181-6.

  11. Budimirovic DB, Berry-Kravis E, Erickson CA, Hall SS, Hessl D, Reiss AL, et al. Updated report on tools to measure outcomes of clinical trials in fragile X syndrome. J Neurodev Disord. 2017; https://doi.org/10.1186/s11689-017-9193-x.

  12. Hoover DW. The effects of psychological trauma on children with autism spectrum disorders: a research review. Rev J Autism Dev Disord. 2015;2:287–99.

    Article  Google Scholar 

  13. Roberts JE, Miranda M, Boccia M, Janes H, Tonnsen BL, Hatton DD. Treatment effects of stimulant medication in young boys with fragile X syndrome. J Neurodev Disord. 2011;3(3):175–84.

    Article  Google Scholar 

  14. Rueda JR, Ballesteros J, Tejada MI. Systematic review of pharmacological treatments in fragile X syndrome. BMC Neurol. 2009;9:53.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jeremy Veenstra-VanderWeele .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Simberlund, J., Veenstra-VanderWeele, J. (2019). Fragile X: Autism in the Setting of a Known Genetic Syndrome. In: Hauptman, A., Salpekar, J. (eds) Pediatric Neuropsychiatry. Springer, Cham. https://doi.org/10.1007/978-3-319-94998-7_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-94998-7_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-94997-0

  • Online ISBN: 978-3-319-94998-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics